Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil[4] Methylprednisolone,
Mycophenolate mofetil,
Mycophenolic acid,
Prednisone		[4] Methylprednisolone ,
Prednisone ,
Mycophenolate mofetil ,
Mycophenolic acid 💬		[3] IMPDH1,
IMPDH2,
NR3C1 💬		[5] Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Purine metabolism 💬[1] 49 💬
2Administration of methylprednisolone, paracetamol and dexchlorpheniramine[3] Acetaminophen,
Dexchlorpheniramine,
Methylprednisolone		[3] Acetaminophen ,
Methylprednisolone ,
Dexchlorpheniramine 💬		[4] HRH1,
NR3C1,
PTGS1,
PTGS2 💬		[26] Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Calcium signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬[1] 49 💬
3Administration of rituximab and methylprednisolone[2] Methylprednisolone,
Rituximab		[2] Methylprednisolone ,
Rituximab 💬		[2] MS4A1,
NR3C1 💬		[2] Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬[1] 51 💬
4Corticosteroid treatment (Methylprednisolone or prednisolone)[2] Methylprednisolone,
Prednisolone		[2] Methylprednisolone ,
Prednisolone 💬		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 64 💬
5Cyclophosphamide, Azathioprine,prednisone,methylprednisolone[4] Azathioprine,
Cyclophosphamide,
Methylprednisolone,
Prednisone		[5] Azathioprine ,
Cyclophosphamide ,
Methylprednisolone ,
Prednisone ,
Cyclophosphamide 💬		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[3] 42, 43, 45 💬
6Infliximab, methylprednisolone, methotrexate[3] Infliximab,
Methotrexate,
Methylprednisolone		[3] Methotrexate ,
Methylprednisolone ,
Infliximab 💬		[4] DHFR,
DHFR2,
NR3C1,
TNF 💬		[72] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Folate biosynthesis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Metabolic pathways, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, One carbon pool by folate, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬[1] 46 💬
7Interferon-beta-1a (Avonex) plus methylprednisolone[3] Human interferon beta,
Interferon beta-1a,
Methylprednisolone		[2] Methylprednisolone ,
Interferon beta-1a 💬		[3] IFNAR1,
IFNAR2,
NR3C1 💬		[19] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬[1] 13 💬
8Intravenous (i.v.) methylprednisolone 1000 mg, total 9[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 222 💬
9Intravenous Methylprednisolone[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[2] 13, 145 💬
10IV methylprednisolone[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 13 💬
11IV methylprednisolone (steroids)[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 13 💬
12Megadose oral methylprednisolone[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 13 💬
13Methotrexate + Methylprednisolone[2] Methotrexate,
Methylprednisolone		[2] Methotrexate ,
Methylprednisolone 💬		[3] DHFR,
DHFR2,
NR3C1 💬		[6] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, Neuroactive ligand-receptor interaction, One carbon pool by folate 💬[1] 46 💬
14Methylprednisolone[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[46] 2, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬
15Methylprednisolone (drug)[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 13 💬
16Methylprednisolone (MP)[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[2] 60, 285 💬
17Methylprednisolone (MP) or prednisone (pred)[2] Methylprednisolone,
Prednisone		[2] Methylprednisolone ,
Prednisone 💬		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 66 💬
18Methylprednisolone (or other glucocorticoid)[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 43 💬
19Methylprednisolone (Solu-Medrol)[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 14 💬
20Methylprednisolone 1250 mg/24h x3 days[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 13 💬
21METHYLPREDNISOLONE ACETATE[2] Acetate,
Methylprednisolone		[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[2] 46, 51 💬
22Methylprednisolone and azathioprine[2] Azathioprine,
Methylprednisolone		[2] Azathioprine ,
Methylprednisolone 💬		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[2] 93, 95 💬
23Methylprednisolone and Mycophenolate mofetil[3] Methylprednisolone,
Mycophenolate mofetil,
Mycophenolic acid		[3] Methylprednisolone ,
Mycophenolate mofetil ,
Mycophenolic acid 💬		[3] IMPDH1,
IMPDH2,
NR3C1 💬		[5] Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Purine metabolism 💬[2] 93, 95 💬
24Methylprednisolone bolus IV 15 mg/kg/d for 3 days.[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 84 💬
25Methylprednisolone hemisuccinate[2] Methylprednisolone,
Methylprednisolone hemisuccinate		[2] Methylprednisolone ,
Methylprednisolone hemisuccinate 💬		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 13 💬
26Methylprednisolone IV[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 13 💬
27METHYLPREDNISOLONE MYLAN Générique[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 66 💬
28Methylprednisolone or budesonide[2] Budesonide,
Methylprednisolone		[2] Budesonide ,
Methylprednisolone 💬		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 96 💬
29Methylprednisolone or Prednisolone[2] Methylprednisolone,
Prednisolone		[2] Methylprednisolone ,
Prednisolone 💬		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 65 💬
30Methylprednisolone PO[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 13 💬
31Methylprednisolone pulse[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[2] 66, 220 💬
32METHYLPREDNISOLONE SODIUM HEMISUCCINATE[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[2] 13, 97 💬
33METHYLPREDNISOLONE SODIUM SUCCINATE[2] Methylprednisolone,
Methylprednisolone hemisuccinate		[2] Methylprednisolone ,
Methylprednisolone hemisuccinate 💬		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[6] 13, 46, 49, 50, 51, 211 💬
34Methylprednisolone succinate[2] Methylprednisolone,
Methylprednisolone hemisuccinate		[2] Methylprednisolone ,
Methylprednisolone hemisuccinate 💬		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 13 💬
35Methylprednisolone(intravenously in the 1st-2nd-3rd month )[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 66 💬
36Methylprednisolone(intravenously in the 1st-3rd-5th month)[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 66 💬
37Oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone[2] Mesalazine,
Methylprednisolone		[2] Mesalamine ,
Methylprednisolone 💬		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 97 💬
38Oral Methylprednisolone 625 mg/24h x3 days[1] Methylprednisolone[1] Methylprednisolone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 13 💬
39Prednisone (and methylprednisolone)[2] Methylprednisolone,
Prednisone		[2] Methylprednisolone ,
Prednisone 💬		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 43 💬
40Prednisone, methylprednisolone,cyclophosphamides[2] Methylprednisolone,
Prednisone		[2] Methylprednisolone ,
Prednisone 💬		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[3] 42, 43, 45 💬
41Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)[2] Methylprednisolone,
Ursodeoxycholic acid		[2] Methylprednisolone ,
Ursodiol 💬		[2] NR1H4,
NR3C1 💬		[2] Bile secretion, Neuroactive ligand-receptor interaction 💬[1] 93 💬